ISU Abxis Co., Ltd. Logo

ISU Abxis Co., Ltd.

Developing antibody-based immunotherapies for oncology and rare diseases.

086890 | KO

Overview

Corporate Details

ISIN(s):
KR7086890001
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 대왕판교로712번길 22, 씨동 5층 (삼평동, 글로벌알앤디센터), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ISU Abxis Co., Ltd. is a biopharmaceutical company that pioneers the discovery and development of engineered antibody-based immunotherapies. The company leverages its advanced antibody technology platform to address significant unmet medical needs in oncology and rare diseases. Its pipeline includes therapeutic candidates such as ISU104 for solid tumors and Fabagal, a treatment for Fabry disease. Founded in 2001, the company is dedicated to developing novel bio-therapeutics to enhance the quality of life for patients with difficult-to-treat conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-08 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB
2025-08-22 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.0 MB
2025-08-11 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB
2025-08-08 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.3 KB
2025-07-21 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 103.4 KB
2025-07-14 00:00
Share Issue/Capital Change
전환청구권행사
Korean 9.4 KB
2025-07-14 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.1 KB
2025-07-11 00:00
Share Issue/Capital Change
전환청구권행사
Korean 14.0 KB
2025-07-08 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-07-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 99.4 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.8 KB
2025-06-30 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 107.4 KB
2025-06-24 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB
2025-06-19 00:00
Regulatory News Service
[기재정정]단일판매ㆍ공급계약체결
Korean 18.0 KB

Automate Your Workflow. Get a real-time feed of all ISU Abxis Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ISU Abxis Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ISU Abxis Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America
ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP

Talk to a Data Expert

Have a question? We'll get back to you promptly.